Alivexis, Inc.

Alivexis, Inc. is a technology-driven drug discovery company that specializes in developing small-molecule targeted therapeutics. The company integrates deep disease biology insights with a proprietary drug discovery platform and simulation engine, known as ModBind, to address complex biological targets. By leveraging advanced structural analysis and supercomputing technologies, Alivexis aims to efficiently identify novel clinical candidate molecules with improved efficacy and safety profiles. The firm operates with a network-based model, maintaining research and operational bases in both Tokyo, Japan, and Cambridge, Massachusetts, and was formerly known as Modulus Discovery, Inc. before rebranding in 2024.

Focused on therapeutic areas including oncology, chronic immune-inflammatory conditions, and rare diseases, Alivexis works to accelerate the delivery of medicine to patients. The company advances its own proprietary pipeline of drug candidates while also engaging in strategic research and development collaborations with industry partners. By combining its computational drug discovery expertise with a global business approach, Alivexis seeks to address significant unmet medical needs and translate its research platform into tangible clinical treatments for patients and their families.